These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 11204671)

  • 1. Irinotecan and thalidomide in metastatic colorectal cancer.
    Govindarajan R
    Oncology (Williston Park); 2000 Dec; 14(12 Suppl 13):29-32. PubMed ID: 11204671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Irinotecan/thalidomide in metastatic colorectal cancer.
    Govindarajan R
    Oncology (Williston Park); 2002 Apr; 16(4 Suppl 3):23-6. PubMed ID: 12014864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. UFT/leucovorin plus irinotecan in advanced or metastatic colorectal cancer.
    Price T; Hill M
    Oncology (Williston Park); 2000 Oct; 14(10 Suppl 9):28-31. PubMed ID: 11098487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of thalidomide on gastrointestinal toxic effects of irinotecan.
    Govindarajan R; Heaton KM; Broadwater R; Zeitlin A; Lang NP; Hauer-Jensen M
    Lancet; 2000 Aug; 356(9229):566-7. PubMed ID: 10950238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy.
    Pitot HC; Goldberg RM; Reid JM; Sloan JA; Skaff PA; Erlichman C; Rubin J; Burch PA; Adjei AA; Alberts SA; Schaaf LJ; Elfring G; Miller LL
    Clin Cancer Res; 2000 Jun; 6(6):2236-44. PubMed ID: 10873073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [[Irinotecan--experience with second-line treatment in advanced colorectal cancer] ].
    Kristó K; Izsó J; Balatoni G; Lohinszky J; Farczádi E; Szántó J; Kofi AP; Pintér T
    Orv Hetil; 2000 Aug; 141(33):1817-20. PubMed ID: 10979311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. CPT-11 F205, F220, F221 and V222 study groups.
    Freyer G; Rougier P; Bugat R; Droz JP; Marty M; Bleiberg H; Mignard D; Awad L; Herait P; Culine S; Trillet-Lenoir V
    Br J Cancer; 2000 Aug; 83(4):431-7. PubMed ID: 10945486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. UFT plus calcium folinate/irinotecan in colorectal cancer.
    Twelves C
    Oncology (Williston Park); 1999 Jul; 13(7 Suppl 3):51-4. PubMed ID: 10442362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma.
    Rothenberg ML; Cox JV; DeVore RF; Hainsworth JD; Pazdur R; Rivkin SE; Macdonald JS; Geyer CE; Sandbach J; Wolf DL; Mohrland JS; Elfring GL; Miller LL; Von Hoff DD
    Cancer; 1999 Feb; 85(4):786-95. PubMed ID: 10091755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-agent irinotecan for recurrent/metastatic colorectal cancer: a retrospective analysis.
    Sanli UA; Karabulut B; Uslu R; Korkut M; Goker E
    Med Princ Pract; 2006; 15(4):288-92. PubMed ID: 16763396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and toxicity of irinotecan in patients with colorectal cancer.
    Rothenberg ML
    Semin Oncol; 1998 Oct; 25(5 Suppl 11):39-46. PubMed ID: 9786315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thalidomide and celecoxib as potential modulators of irinotecan's activity in cancer patients.
    Villalona-Calero M; Schaaf L; Phillips G; Otterson G; Panico K; Duan W; Kleiber B; Shah M; Young D; Wu WH; Kuhn J
    Cancer Chemother Pharmacol; 2007 Jan; 59(1):23-33. PubMed ID: 16685529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of epirubicin and thalidomide in unresectable or metastatic hepatocellular carcinoma.
    Zhu AX; Fuchs CS; Clark JW; Muzikansky A; Taylor K; Sheehan S; Tam K; Yung E; Kulke MH; Ryan DP
    Oncologist; 2005; 10(6):392-8. PubMed ID: 15967833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FOLFIRI plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer: a JACCRO CC-03 multicenter phase II study.
    Kochi M; Akiyama Y; Aoki T; Hagiwara K; Takahashi T; Hironaka K; Teranishi F; Osuka F; Takeuchi M; Fujii M; Nakajima T
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):1097-102. PubMed ID: 24057041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A pilot study of irinotecan hydrochloride for metastatic breast cancer--efficacy as a salvage therapy].
    Ikeda H; Koshiba R
    Gan To Kagaku Ryoho; 2000 May; 27(5):723-7. PubMed ID: 10832441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of irinotecan as first-line chemotherapy for patients with advanced colorectal carcinoma.
    Fírvida JL; Irigoyen A; Vázquez-Estévez S; Díz P; Constenla M; Casal-Rubio J; Valladares-Ayerbes M; Castellanos J; Rodríguez R; Balcells M
    Cancer; 2001 Feb; 91(4):704-11. PubMed ID: 11241237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Irinotecan in the first-line treatment of colorectal cancer.
    Saltz LB
    Oncology (Williston Park); 1998 Aug; 12(8 Suppl 6):54-8. PubMed ID: 9726092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer: results of a phase II study.
    Taïeb J; Artru P; Paye F; Louvet C; Perez N; André T; Gayet B; Hebbar M; Goebel FM; Tournigand C; Parc R; de Gramont A
    J Clin Oncol; 2005 Jan; 23(3):502-9. PubMed ID: 15659495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Irinotecan and other agents in upper gastrointestinal and colorectal carcinomas. The University of Texas M. D. Anderson Cancer Center Investigators' Workshop, Volume 3. Introduction.
    Ajani JA
    Oncology (Williston Park); 2003 Sep; 17(9 Suppl 8):10-2. PubMed ID: 14569840
    [No Abstract]   [Full Text] [Related]  

  • 20. Irinotecan for the treatment of cervical cancer.
    Verschraegen CF
    Oncology (Williston Park); 2002 May; 16(5 Suppl 5):32-4. PubMed ID: 12109804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.